Stockscreener 앱 받기
13.66
8.81%
-1.32
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
SMMT|Summit Therapeutics Inc|Price:13.660|Chg%:-1.320 - TradingKey
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating Afte - GuruFocus
SMMT Maintained by Guggenheim -- Price Target Lowered to $38.00 - GuruFocus
SMMT Maintained by Stifel -- Price Target Lowered to $38.00 - GuruFocus
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.06, Implies 94% Upside - TradingView
Summit Therapeutics Inc. Stock 12‑Month Price Target Cut to $29.2, Implies 95% Upside - TradingView
SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data - Stocktwits
Summit Therapeutics Flags Going Concern Risk Over Cash Needs - Benzinga
Summit Therapeutics Inc. Revenue Breakdown – NASDAQ:SMMT - TradingView
Stifel cuts Summit Therapeutics stock price target on timing concerns By Investing.com - Investing.com Canada
Summit Therapeutics (SMMT) Analyst Maintains Neutral Rating After Q2 Report - GuruFocus
SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus - TradingView
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 - BioSpace
Guggenheim lowers Summit Therapeutics stock price target on trial timing By Investing.com - Investing.com Canada
Summit Therapeutics Signs Distribution Agreement With J.P. Morgan Securities for Common Stock Offering - Minichart
Deckers Outdoor, Summit Therapeutics, Robert Half And Other Big Stocks Moving Lower In Friday’s Pre-Marke - Benzinga
Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug - Yahoo Finance
Summit (SMMT) Completes Enrollment in Global HARMONi-3 Study - GuruFocus
Summit Q2 2026 slides: ivonescimab OS data strengthens amid spending rise - Investing.com Nigeria
Summit Therapeutics (SMMT) Reports Q2 EPS Beat with Strong Cash Position - GuruFocus
Summit Therapeutics (SMMT) Faces Financial Uncertainty Amid Funding Challenges - GuruFocus
Summit Therapeutics (SMMT) Reports Positive Clinical Developments and Strong Cash Position - GuruFocus
Summit Therapeutics Inc (SMMT) Q2 2026 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Summit Therapeutics Launches $380 Million At-the-Market Equity Offering Program with J.P. Morgan Securities - Kalkine Media
Summit Therapeutics Announces Q2 2026 Financial Results and Operational Highlights - Kalkine Media
Summit Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Summit (SMMT) Advances Clinical Trials with Promising Ivonescima - GuruFocus
Concerns Rise for Summit Therapeutics (SMMT) Regarding Financial Viability - GuruFocus
Summit Therapeutics (SMMT) Faces Funding Challenges Amid Q2 Losses - GuruFocus
Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain? - Yahoo Finance
SMMT Q2 FY2026 earnings call - finance.biggo.com
[SMMT Q2 2026 Earnings Call] Summit Therapeutics Cash Hits $690.7M, Updated HARMONi Data Shows HR 0.76 Overall Survival Ahead of PDUFA - finance.biggo.com
Summit Therapeutics Initiates $380 Million At-The-Market Stock Offering with J.P. Morgan - Kalkine Media
Earnings call transcript: Summit Therapeutics Q2 2026 loss widens as shares fall after hours - Investing.com Canada
SMMT: Summit Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Summit Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SMMT) 2026-07-23 - Seeking Alpha
Summit Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
Transcript : Summit Therapeutics Inc., Q2 2026 Earnings Call, Jul 23, 2026 - marketscreener.com
Summit Therapeutics says cash crunch could impact its ability to continue - Seeking Alpha
Summit Therapeutics (SMMT) Q2 2026 earnings summary - Quartr
Summit Therapeutics Reports Ivonescimab Progress and Strong Cash - TipRanks
Summit Therapeutics (SMMT) sets up $380M at-the-market share offering - Stock Titan
Summit Therapeutics: substantial doubt about our ability to continue as a going concern - StreetInsider
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q2 Adjusted Loss $0.19 per Share, vs. FactSet Est of $-0.17 - marketscreener.com
Summit Therapeutics (NASDAQ: SMMT) posts loss, eyes FDA decision - Stock Titan
Summit Therapeutics posts Q2 loss, reports ivonescimab trial data - StreetInsider
SMMT Reiterated by HC Wainwright & Co. -- Rating Maintained at N - GuruFocus
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study - Yahoo Finance
H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics By Investing.com - Investing.com Nigeria
Why (SMMT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics - Investing.com
SMMT Reiterated by HC Wainwright & Co. -- Rating Maintained at Neutral - GuruFocus
Summit Therapeutics (SMMT) Stock Looks Stretched On Fresh Lung Cancer Data - Yahoo Finance
Did New HARMONi Survival Data Just Shift Summit Therapeutics' (SMMT) Ivonescimab Investment Narrative? - Yahoo Finance UK
Why Is SMMT Stock Tumbling Today? - Stocktwits
Summit Therapeutics (SMMT) Updates on Ivonescimab Lung Cancer Tr - GuruFocus
Summit Therapeutics (SMMT) Reports Positive Updates from HARMONi Clinical Trial - GuruFocus
0.46%
0.84%
자본화:
|
볼륨(24시간):